Skip To Main Content
Jin Qiu on Muck Rack

Jin Qiu

As seen in: Nature, Wiley Online Library, arXiv, PLOS Biology, ScienceDirect, Frontiers, Journal of Clinical Pathology, MDPI, South China Morning Post, BMC Psychology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jin

Contact Jin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AAV-Mediated Meis2 Gene Therapy Restores PV Neuron Plasticity in Adult Neurodevelopmental Disorder Mouse Model

|
By Jin Qiu
| PackGene Biotech
Aug 13, 2026 — A new study published in Nature reports that restoring activity of the transcription factor Meis2 in adult brain inhibitory neurons may reverse key neurological deficits in a mouse model of neurodevelopmental disorders. The study, led by researchers at Mass General Brigham, identified Meis2 as a molecular regulator of experience-dependent plasticity in parvalbumin-positive, or PV, inhibitory neurons.
Open in Who Shared Issue with article?

Neurogene Reports Durable Developmental Gains with AAV9 Gene Therapy NGN-401 in Rett Syndrome

|
By Jin Qiu
| PackGene Biotech
Aug 11, 2026 — Neurogene reported second-quarter 2026 financial results and highlighted continued clinical progress for NGN-401, its investigational AAV9 gene therapy for Rett syndrome. NGN-401 is being developed as a potential one-time treatment for Rett syndrome.
Open in Who Shared Issue with article?

Sumitomo Pharma America Treats First Patient with Retinal Cell Therapy DSP-3077 in Retinitis Pigmentosa

|
By Jin Qiu
| PackGene Biotech
Aug 12, 2026 — Sumitomo Pharma America announced that the first patient has undergone subretinal implantation in a Phase 1/2a clinical study evaluating DSP-3077, its investigational allogeneic iPS cell-derived retinal sheet therapy for non-syndromic retinitis pigmentosa, or RP. DSP-3077 is an investigational regenerative cell therapy composed of allogeneic induced pluripotent stem cell-derived retinal sheets.
Open in Who Shared Issue with article?
See all 566 licensed articles (571 Total)